Alcista
$14.32
Precio del escenario
$27.760
+0.719 (+2.59%)Al cierre
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Pediatrix Medical Group Inc is currently trading at $26.64, which is close to the average analyst price target of $28, suggesting limited upside potential. The RSI is at 68.631, indicating it is approaching overbought territory, which could lead to a price correction. Additionally, the stock has shown a strong year-to-date change of +25.13% and a one-year change of +65.98%, but the recent downgrade from Jefferies highlights potential risks ahead, particularly with earnings growth expected to cap due to tax credit headwinds.
Jefferies
$28
2026-08-19
Jefferies
2026-08-19
Precio objetivo
$28
UBS
$28
2026-08-06
UBS
2026-08-06
Precio objetivo
$28
Deutsche Bank
$25
2026-08-05
Deutsche Bank
2026-08-05
Precio objetivo
$25
UBS
$25
2026-05-12
UBS
2026-05-12
Precio objetivo
$25
Mizuho
$24
2026-05-08
Mizuho
2026-05-08
Precio objetivo
$24
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Pediatrix Medical Group Q2 Earnings Highlights

Surge in Options Trading Volume for Celanese and Pediatrix

Pediatrix Medical Group Q2 2026 Earnings Call Insights

Pediatrix Medical Group Reports Q2 2026 Earnings

Pediatrix Medical Group Q2 Earnings Exceed Expectations
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. It operates in the Healthcare sector (SERVICES-HOSPITALS industry).
Pediatrix Medical Group Inc is currently trading at $26.64, which is close to the average analyst price target of $28, suggesting limited upside potential. The RSI is at 68.631, indicating it is approaching overbought territory, which could lead to a price correction. Additionally, the stock has shown a strong year-to-date change of +25.13% and a one-year change of +65.98%, but the recent downgrade from Jefferies highlights potential risks ahead, particularly with earnings growth expected to cap due to tax credit headwinds.
14 analysts cover MD: 3 rate it Buy, 10 Hold and 1 Sell. The average price target is 23.50.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.